

## **NBHL RAISES \$6.82 M IN SERIES C FINANCING TO ADVANCE PIPELINE OF NOVEL GPCR ANTIBODIES FOR SERIOUS DISEASES**

**SAPPORO, JAPAN, August 24, 2021** – NB Health Laboratory Co. Ltd. (NBHL), a biotechnology company dedicated to discovering, developing and commercializing innovative medicines to treat various diseases with very limited or no solutions, today announced the closing of a \$6.82million Series C financing to expand its G protein-coupled receptors (GPCRs) antibody platform to discover novel therapeutics and to accelerate development of advanced antibody candidates.

The financing was led by new investor TIANJIN HAIHE ASYMCHEM PHARM/BIOMED INDUSTRY FUND L.P. (“HAPI”, a China-based venture fund) and includes participation from returning investor ANNIVERSAIRE HOLDINGS INC. HAPI is managed by Trinity Innovation (Beijing) Investment Management Co. Ltd. (“TIF”). Dr. Xukun (David) Wang from HAPI will join the NBHL Board of Directors.

“We appreciate the support and confidence demonstrated by our new and existing investors in this round,” said Kiyoshi Takayama, Ph.D, founder and president of NBHL. “Proceeds from the financing will enable us to further advance the preclinical development of our lead antibodies for autoimmune disease, fibrosis and severe viral infection as well as support the continued expansion of our pipeline of GPCR antibodies.”

“We were deeply impressed by NBHL’s solid science, experienced management team, and broad potential therapeutic applicability of its proprietary technology platform that generates functional monoclonal antibodies targeting GPCR,” said Dr. Wang, Managing Partner of TIF and Trinity Innovation Bioventure Singapore (“TIBS”, a Singapore-based venture capital fund manager). “Mutual trust has been built through long term sincere interactions. We are dedicated to support NBHL’s further growth with our rich network and resources in Asia Pacific region. Hopefully our very first investment in Japan will pave the way for more collaborations with Japanese biotechs.”

### **About HAPI and TIF/TIBS.**

HAPI was jointly founded in 2019 by TIANJIN HAIHE VENTURE FUND L.P., ASYMCHEM (a global leading CDMO company) and TIANJIN CHINA-SINGAPORE ECO CITY dedicated to pharmaceutical and biotechnology sector investment. Since its inception, HAPI has closed multiple investment cases covering CSO (contract sales organization), CRO (contract research organization), biotech companies with different focuses (small molecule, biologics, clinical development etc.). HAPI is managed by TIF/TIBS teams.

TIF/TIBS is biotechnology focused VC fund manager, aims to invest on cutting-edge biomedical technology,

innovative drug discovery & development platform and novel pharma industrial solutions globally. For more information, please visit “[www.trinity-fund.com](http://www.trinity-fund.com)” and “[www.trinity-fund.com.sg](http://www.trinity-fund.com.sg)”.

**About ANNIVERSAIRE HOLDINGS INC.**

A group company of AOKI HOLDINGS INC. established in 1965, and dedicated to holding securities and real estate leasing business.

CEO: Mr. Masamitsu Aoki

Headquarters: Tokyo, Japan

**About NBHL**

NB Health Laboratory Co. Ltd. (NBHL) is a biotechnology company dedicated to discovering, developing and commercializing innovative medicines to treat respiratory diseases, chronic inflammation and respiratory infectious disease such as COVID-19 and influenza. NBHL has expertise in the generation of functional antibodies targeting G protein-coupled receptors (GPCRs) and is pioneering a new field in GPCR-targeted drug discovery to benefit human health. For more information about the company, please go to <https://nbhl.co.jp/>.